Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor-Positive Breast Cancer
Matissek KJ, Onozato ML, Sun S, Zheng Z, Schultz A, Lee J, Patel K, Jerevall PL, Saladi SV, Macleay A, Tavallai M, Badovinac-Crnjevic T, Barrios C, Be?e N, Chan A, Chavarri-Guerra Y, Debiasi M, Demirdögen E, Egeli Ü, Gökgöz S, Gomez H, Liedke P, Tasdelen I, Tolunay S, Werutsky G, St Louis J, Horick N, Finkelstein DM, Le LP, Bardia A, Goss PE, Sgroi DC, Iafrate AJ, Ellisen LW.
Survival outcomes related to health care coverage in breast cancer patients with brain metastases in Brazil: A sub-analysis from the LACOG-0312 study
Caroline Albuquerque, Marcio Debiasi, Gustavo Werutsky, Deise Uema, Eduardo Cronenberger, Vladmir C Cordeiro de Lima, Rosane O de Sant'ana, José Bines, Patricia X Santi, Renata S Goés, Pedro Liedke, Maria LM Batista, Vanessa Dybal, Yeni V Nerón, Carlos A Beato, Giuliano Borges, Juliana Giacomazzi, Lucas V dos Santos, Gustavo Ismael, Daniela D Rosa, Alan Azambuja, Diocésio Andrade, Jeovany Martinez-Mesa, Facundo Zaffaroni and Carlos H Barrios SABCS 2017 Full link: https://cancerres.aacrjournals.org/content/78/4_Supplement/P1-17-10
Survival outcomes related to health care coverage in metastatic breast cancer in Brazil: A sub-analysis from the LACOG-0312 study
Gustavo Werutsky, Facundo Zaffaroni, Deise Uema, Eduardo Cronenberger, Vladmir C Cordeiro de Lima, Rosane O de Sant'ana, José Bines, Patricia X Santi, Renata S Goés, Pedro Liedke, Maria LM Batista, Vanessa Dybal, Yeni V Nerón, Carlos A Beato, Giuliano Borges, Juliana Giacomazzi, Lucas V dos Santos, Gustavo Ismael, Daniela D Rosa, Alan Azambuja, Diocésio Andrade, Jeovany Martinez-Mesa, Marcio Debiasi and Carlos H Barrios SABCS 2017 Full link: https://cancerres.aacrjournals.org/content/78/4_Supplement/P4-10-17
Reproductive status and clinical pathological characteristics of young women diagnosed with breast cancer in Latin America: LACOG 0414 Study
Carlos H. Barrios, Deise Uema, Eduardo Cronenberger, Vladmir Lima, José Bines, Rosane de Sant'ana, Maria Lúcia Martins Batista, Vanessa Dybal, Pedro E. R. Liedke, Carlos Beato, Yeni Veronica Nerón, Juliana Giacomazzi, Lucas dos Santos, Gustavo Ismael, Alan Azambuja, Diocésio Andrade, Daniela Dornelles Rosa, Giuliano Borges, Max Mano, Jeovany Martinez-Mesa, Facundo Zaffaroni, Márcio Debiasi, Gustavo Werutsky SABCS 2017 Full link: https://cancerres.aacrjournals.org/content/78/4_Supplement/P6-08-24
Exploring disparities in incidence and mortality rates of breast and gynecologic cancers according to the Human Development Index in the Pan-American region
Martínez-Mesa J, Werutsky G, Stefan M, Pereira Filho CAS, Dueñas-González A, Zarba JJ, Mano M, Villarreal-Garza C, Gómez H, Barrios CH.
Real World data and patterns of care of metastatic breast cancer (MBC) in Brazil: First results of LACOG 0312 retrospective study
Barrios CH, Uema D, Cronenberger E, Lima V, Bines J, de Sant'ana RO, Batista ML, Dybal V, Liedke P, Beato C, Nerón YV, Giacomazzi J, dos Santos L, Ismael G, Azambuja A, Andrade D, Rosa DD, Borges G, Mano M, Martinez-Mesa J, Zaffaroni F, Werutsky G Cancer Res February 2017Volume 77, Issue 4 Supplement Full link: https://cancerres.aacrjournals.org/content/77/4_Supplement/P6-16-04
Estratégias para vencer a resistência à terapia anti-HER2
Márcio Debiasi, Paulo Nunes Filho, Carolina Albuquerque e Valeria Sgnaolin
Estimation of Premature Deaths From Lack of Access to Anti-HER2 Therapy for Advanced Breast Cancer in the Brazilian Public Health System
Márcio Debiasi, Tomás Reinert, Rafael Kaliks, Gilberto Amorim, Maira Caleffi, Carlos Sampaio, Gustavo dos Santos Fernandes and Carlos H. BarriosJournal of Global Oncology 3, no. 3 (June 2017) 201-207. Full link: https://ascopubs.org/doi/full/10.1200/JGO.2016.005678
A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study)
Novel targeted agents and combinations have become available in multiple lines of treatment for human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC). In this context, alternatives to the lapatinib (L) and capecitabine (C) regimen, evaluating L combined with other cytotoxic drugs, are warranted.
Incidence and mortality rates of breast and gynecologic cancers and human development index in the pan-American region
Jeovany Martínez-Mesa, Gustavo Werutsky, Carlos Alberto Sampaio-Filho, Aknar Calabrich, Carlos H. Barrios J Clin Oncol 31, 2013 (suppl; abstr e12510) Full link: https://meetinglibrary.asco.org/record/96361/abstract